Therapeutic options for metastatic pancreatic ductal adenocarcinoma (PDAC) remain limited, with second-line treatments typically yielding modest benefit. Activation of the RAS pathway, most commonly driven by KRAS mutations, occurs in the vast majority of PDAC cases and represents a critical oncogenic dependency. Daraxonrasib, an oral, multi-selective RAS(ON) inhibitor targeting the active, GTP-bound state of RAS,...
